[Form 4] MEI Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MEI Pharma director Joshua Riezman was granted a stock option to buy 10,000 shares of common stock at an exercise price of $5.19. The option was granted on 08/08/2025, becomes exercisable in installments and expires on 08/08/2035. The grant vests in 36 equal monthly installments, with the first installment vesting one month after the grant, subject to continued service.

Positive

• 10,000-share option grant documented with explicit exercise price and long-term expiration
• 36-month monthly vesting is specified, providing a clear schedule tied to continued service

Negative

• Potential dilution of 10,000 shares if options are exercised
• No performance-based vesting disclosed in the filing (vesting is solely time-based)

Insights

Financial Analyst

TL;DR: Routine director option grant for 10,000 shares with 10-year term and standard monthly vesting.

The transaction reports a non-derivative grant structured as a stock option exercisable for 10,000 shares at $5.19 per share, with an expiration ten years from grant and a 36-month monthly vesting schedule. For investors, this is a compensation event rather than an operational development; it modestly increases potential share count if exercised but provides no direct cash flow or revenue impact.

Corporate Governance Expert

TL;DR: Standard equity-based compensation for a director with multi-year vesting to require continued service.

The form indicates the award vests in equal monthly installments over three years, which is a common mechanism to link service to option vesting. Documentation shows the filing was executed by an attorney-in-fact on behalf of the reporting person. There is no indication of acceleration, special performance conditions, or related-party transaction terms in the disclosed text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riezman Joshua

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD., SUITE 150

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MEI Pharma, Inc. [ MEIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.19	08/08/2025		A		10,000		(1)	08/08/2035	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

	/s/ Justin J. File, as Attorney-in-fact for the Reporting Person	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What option was granted to Joshua Riezman on MEIP Form 4?

A stock option to purchase 10,000 shares of MEI Pharma common stock at an exercise price of $5.19 per share.

When does the option become exercisable and when does it expire?

The option was granted on 08/08/2025, vests in 36 equal monthly installments starting one month after grant, and expires on 08/08/2035.

Is the vesting conditional on performance or time?

The filing states vesting is in 36 equal monthly installments subject to continued service; no performance conditions are disclosed.

Who filed the Form 4 on behalf of the reporting person?

The signature block shows the form was signed by Justin J. File, as attorney-in-fact for the reporting person.

Does the Form 4 indicate any indirect ownership or other transactions?

The filing reports the option as direct beneficial ownership and discloses only the single option grant; no indirect holdings or other transactions are shown.